journal cover

Coadministered cannabidiol and clobazam: Preclinical evidence for both pharmacodynamic and pharmacokinetic interactions

Epilepsia

Oct 17, 2019

Lyndsey L AndersonJonathon C Arnold

Get paper from

Abstract

Cannabidiol (CBD) has been approved by the US Food and Drug Administration (FDA) to treat intractable childhood epilepsies, such as Dravet syndrome and Lennox-Gastaut syndrome. However, the intrinsic anticonvulsant activity of CBD has been questioned due to a pharmacokinetic interaction...read more

Mentioned in this Paper

Anticonvulsants
Brain
Cannabidiol
Combination Drug Therapy
Epilepsy
Metabolism
Laboratory mice
Drug Kinetics
Plasma
United States Food and Drug Administration
88
1
2
16

Similar Papers Found In These Feeds

Lennox-Gastaut Syndrome

Lennox-Gastaut syndrome is a severe epileptic syndrome characterized by multiple, recurrent seizure types, a slow spike-and-wave by electroencephalogram, and cognitive impairment. Causes can include congenital abnormalities, genetic mutations, hypoxia, or infections. Onset typically occurs between 3-5 years of age. Find the lastest research on Lennox-Gastaut syndrome.

Dravet Syndrome

Dravet syndrome, previously known as severe myoclonic epilepsy of infancy (SMEI), is a rare, catastrophic, lifelong form of epilepsy with frequent and/or prolonged seizures that are often triggered by hot temperatures or fever. Discover the latest research on Dravet syndrome here.

Epilepsy

Epilepsy is a chronic neurological disorder characterized by unprovoked and recurrent seizures. Discover the latest research on factors and mechanisms that underlie epilepsy here.

Cytochrome Activity

This feed focuses on cytochromes, including cytochrome C and the cytochromes P450 (CYP) enzyme system, and their involvement in the activation and inactivation of drugs.

Angelman Syndrome

Angelman syndrome is a neurogenetic imprinting disorder caused by loss of the maternally inherited UBE3A gene and is characterized by generalized epilepsy, limited expressive speech, sleep dysfunction, and movement disorders. Here is the latest research.

© 2019 Meta ULC. All rights reserved

Coadministered cannabidiol and clobazam: Preclinical evidence for both pharmacodynamic and pharmacokinetic interactions

Epilepsia

Oct 17, 2019

Lyndsey L AndersonJonathon C Arnold

PMID: 31625159

DOI: 10.1111/epi.16355

Abstract

Cannabidiol (CBD) has been approved by the US Food and Drug Administration (FDA) to treat intractable childhood epilepsies, such as Dravet syndrome and Lennox-Gastaut syndrome. However, the intrinsic anticonvulsant activity of CBD has been questioned due to a pharmacokinetic interaction...read more

Mentioned in this Paper

Anticonvulsants
Brain
Cannabidiol
Combination Drug Therapy
Epilepsy
88
1
2
16

Related Papers

Get paper from

/papers/coadministered-cannabidiol-and-clobazam/31625159